Charles River Laboratories International, Inc.
CRLCharles River Laboratories International, Inc. is a global research and development organization specializing in providing essential products and services for the pharmaceutical, biotechnology, and healthcare industries. Founded in 1947, the company offers early-stage contract research, preclinical and clinical support, and laboratory services to assist in the discovery, development, and manufacturing of new drugs and therapies. Its facilities and expertise enable clients to streamline drug development processes and meet regulatory requirements efficiently.
Company News
The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. St...
The cell and gene therapy CDMO market is projected to grow from USD 8.3 billion in 2025 to USD 57.1 billion by 2034, driven by increasing clinical development of advanced therapies, rising outsourcing trends among biopharma companies, and technological advancements in manufacturing. North America leads the market with 40% share, while Asia-Pacifi...
The cell banking outsourcing market is projected to grow from USD 16.78 billion in 2025 to USD 42.31 billion by 2031, with a CAGR of 16.71%. Growth is driven by increasing demand for biologics, cell and gene therapies, and regenerative medicine. North America leads the market while Asia-Pacific emerges as a high-growth region. Biopharmaceutical c...
The plasmid DNA manufacturing market is projected to grow from USD 2.4 billion in 2025 to USD 10.8 billion by 2034, driven by rising demand for gene therapies, DNA vaccines, and CAR-T treatments. North America leads the market with 44.12% share, while Asia-Pacific emerges as a significant growth engine. Major companies are expanding GMP-compliant...
The AAV vector manufacturing market is projected to grow from USD 874 million in 2025 to USD 5.2 billion by 2034, driven by expanding gene therapy research, increasing regulatory approvals, and rising investments in biomanufacturing infrastructure. North America leads the market with 43% share, while Asia-Pacific emerges as a key growth engine. K...
